Dr. Coles is Chairman and CEO of Yumanity Therapeutics, a company focused on identifying and developing new therapies for neurodegenerative diseases such as Parkinson's. Dr. Coles holds the same two titles -- Chairman and CEO -- for TRATE Enterprises, LLC., and previously for Onyx Pharmaceuticals, Inc., which was acquired by Amgen in 2013 for $10.5 billion. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the U.S. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held a number of executive positions at Bristol-Myers Squibb Company. Additionally, from 1992 until 1996, Dr. Coles held a number of positions of increasing responsibility at Merck & Co., Inc.
Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned his M.D. from Duke University, a master’s degree in public health from Harvard University and an undergraduate degree from Johns Hopkins University.
Dr. Coles currently serves as a member of the board of directors of McKesson Corporation (NYSE: MCK), is vice chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. Dr. Coles also serves as a director of the board of the U.S. Olympic and Paralympic Foundation.